Amundi
INDV icon

Amundi’s Indivior Pharmaceuticals INDV Stock Holding History

Amundi’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-177,914
Closed -$2.74M – 1633
2025
Q2 		$2.74M Buy
177,914
+19,459
+12% +$227K ﹤0.01% 1024
2025
Q1 		$1.49M Sell
158,455
-15,979
-9% -$168K ﹤0.01% 1228
2024
Q4 		$2.11M Buy
174,434
+19,010
+12% +$196K ﹤0.01% 1177
2024
Q3 		$1.53M Sell
155,424
-70,187
-31% -$822K ﹤0.01% 1204
2024
Q2 		$3.44M Buy
225,611
+22,975
+11% +$415K ﹤0.01% 1018
2024
Q1 		$3.8M Buy
202,636
+26,015
+15% +$489K ﹤0.01% 1021
2023
Q4 		$2.72M Buy
176,621
+37,741
+27% +$670K ﹤0.01% 1115
2023
Q3 		$2.69M Buy
+138,880
New +$3.17M ﹤0.01% 1105

Other funds holding INDV

TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Amundi's INDV Position: Q3 2025 in Review

Amundi sold out of Indivior Pharmaceuticals (INDV) in Q3 2025, closing a stake of 177,914 shares — an estimated $2.74M sold.

Amundi first reported a position in INDV in Q3 2023 and held it in 8 quarters. The position peaked at $3.8M in Q1 2024. 198 funds tracked by Wall St. Rank hold INDV as of Q3 2025.

  • Amundi reported no remaining Indivior Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Amundi sold 177,914 Indivior Pharmaceuticals shares in Q3 2025, an estimated $2.74M.
  • Amundi first reported a position in Indivior Pharmaceuticals in Q3 2023 and held it in 8 quarters.
  • Amundi's Indivior Pharmaceuticals position peaked at $3.8M in Q1 2024.
  • 198 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q3 2025.

Based on Amundi's 13F filing for Q3 2025, filed 14 Nov 2025.